Filter
1941
Text search:
Vaccine
safety
Featured
Recommendations
242
New Publications
454
Language
Document type
No document type
781
Guidelines
344
Studies & Reports
341
Manuals
136
Strategic & Response Plan
124
Fact sheets
103
Situation Updates
37
Training Material
29
Resource Platforms
13
Videos
10
Infographics
9
Online Courses
7
Brochures
6
App
1
Countries / Regions
Global
94
India
56
Kenya
54
Sierra Leone
50
Nigeria
45
Liberia
44
Latin America and the Carribbean
44
South Africa
39
Africa
37
Uganda
35
Ethiopia
31
Western and Central Europe
31
Tanzania
28
Congo, Democratic Republic of
25
Ghana
25
Zambia
24
West and Central Africa
21
Philippines
20
Nepal
20
Syria
20
Bangladesh
19
Brazil
19
Ukraine
19
Myanmar / Burma
18
East and Southern Africa
18
Malawi
17
Middle East and North Africa
17
Rwanda
16
Pakistan
15
South Sudan
15
Namibia
14
Russia
14
South–East Asia Region
13
Zimbabwe
12
Guinea
11
Mozambique
11
Senegal
10
Eastern Europe and Central Asia
10
Germany
9
Lesotho
9
Yemen
8
Sudan
7
Eastern Europe
7
Lebanon
6
Cambodia
6
China
6
Indonesia
6
Botswana
6
Burkina Faso
5
Cameroon
5
Haiti
5
Central African Republic
5
Argentina
5
Colombia
5
Chile
5
Western Pacific Region
5
Paraguay
5
Asia
5
Vietnam
5
USA
4
Somalia
4
Afghanistan
4
Ecuador
4
Bolivia
4
Venezuela
4
Jordan
3
Turkey
3
Thailand
3
Peru
3
Eswatini/ Swaziland
3
El Salvador
3
Palestine
3
Laos
3
Moldova
3
United Kingdom
3
Spain
3
Mali
2
Côte d’Ivoire / Ivory Coast
2
Niger
2
Iraq
2
Egypt
2
Papua New Guinea
2
North Macedonia
2
Libya
2
Madagascar
2
Nicaragua
2
Sri Lanka
2
Timor Leste/ East Timor
2
France
2
Guinea-Bissau
1
Morocco
1
Saudi Arabia
1
Togo
1
Chad
1
Gambia
1
Malaysia
1
Dominican Republic
1
Switzerland
1
Cuba
1
Burundi
1
Honduras
1
Angola
1
Guatemala
1
Mexico
1
Fiji
1
Bhutan
1
Djibouti
1
Tajikistan
1
Qatar
1
Bulgaria
1
Iran
1
Kazakhstan
1
Georgia
1
North America
1
Gabon
1
Jamaica
1
Japan
1
Mauritius
1
Tunisia
1
Portugal
1
South Korea
1
Belarus
1
French Guyana
1
Authors & Publishers
Publication Years
Category
Countries
685
Clinical Guidelines
192
Key Resources
101
Women & Child Health
100
Public Health
94
Pharmacy & Technologies
25
Capacity Building
22
Toolboxes
COVID-19
456
Ebola & Marburg
108
HIV
92
TB
86
Rapid Response
76
AMR
64
Pharmacy
56
NTDs
53
Conflict
48
2.0 Rapid Response
41
Planetary Health
40
Refugee
37
Global Health Education
33
Caregiver
30
Polio
29
Zika
25
Natural Hazards
24
Cholera
23
Health Financing Toolbox
23
Malaria
23
Mental Health
20
NCDs
10
Specific Hazards
8
Disability
6
South Sudan
1
For most people in displacement contexts, there are simply not enough vaccines available in the places where they are hosted: 85% of refugees are hosted in lower- and middle-income countries, while in the first six months of this year 85% of vaccines went to wealthy countries; lower- and middle inco
...
The COVID-19 Vaccine (Whole Virion Inactivated) BBV152, COVAXIN® vaccine explainer includes key information on the vaccine specific requirements.
Occupational health and safety programmes aim to prevent diseases and injuries arising out of, linked with or occurring in the course of work, while improving the quality and safety of care, safegua
...
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19
...
Data for Action March 2022, Issue 5
9 Febr. 2022
The COVID Covovax™ (SIIPL) and Nuvaxovid™ (Novavax) vaccine explainer includes key vaccine specific information on the vaccine sp
...
The objective of this document is to guide the preparation and implementation of national preparedness plans for the safety of substances of human origin during outbreaks of Zika virus infection, both in affected and non-affected areas.
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence s
...
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
first issued 18 August 2022
Herd immunity by mass vaccination offers the potential to substantially limit the continuing spread of COVID-19, but high levels of vaccine hesitancy threaten this goal. In a cross-country analysis of vacc
...
An example of integration of research into epidemic response.
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the back
...
Rabies is fatal, vaccine-preventable disease responsible for an estimated 59,000 human deaths each year. Most cases are transmitted by dogs, and most deaths occur in underserved populations in Africa and Asia. Approximately 40% of deaths occur in ch
...
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary include
...
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
